Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 17/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284408 | 0.93 | SMN1; SMN2 (0.51) | AURKBHDAC1ROCK2ROCK1 | |
| SCHEMBL4282342 | 0.92 | SMN1; SMN2 (0.53) | AURKBROCK2ROCK1 | |
| SCHEMBL4283666 | 0.90 | AURKB (0.63) | AURKBHDAC1ROCK2ROCK1 | |
| SCHEMBL4280378 | 0.85 | AURKB (0.58) | AURKBHDAC1ROCK2ROCK1 | |
| SCHEMBL4279183 | 0.85 | AURKB (0.61) | AURKBPIK3CAHDAC1ROCK2ROCK1 | |
| SCHEMBL4286072 | 0.83 | AURKB (0.56) | AURKBPIK3CAHDAC1ROCK2ROCK1 | |
| SCHEMBL4278779 | 0.83 | AURKB (0.56) | AURKBPIK3CAHDAC1 | |
| SCHEMBL4278966 | 0.82 | AURKB (0.59) | AURKBROCK2ROCK1 | |
| SCHEMBL4291617 | 0.77 | CLK4 (0.57) | AURKBPIK3CAROCK2ROCK1 | |
| SCHEMBL4284196 | 0.76 | AURKB (0.64) | AURKBROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | US | claimed |
| WO-2009126635-A1 | 2-AMINO-BENZOTHIAZOLE DERIVATES USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | WO | claimed |
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009126635-A1 | 2-AMINO-BENZOTHIAZOLE DERIVATES USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ROCK1, ROCK2, RHOA | AURKB 276/4885PIK3CA 293/4885HDAC1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.